Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Lymphoma, B-Cell 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 12Rituximab 10Gemcitabine 9Paclitaxel 8Bendamustine Hydrochloride 8Lenalidomide 7Decitabine 7Cytarabine 7Carboplatin 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Bevacizumab 4Antilymphocyte Serum 4venetoclax 3pomalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Recurrence × gemcitabine-oxaliplatin regimen × Clear all
NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
102 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡